Many of us have been attracted to the study of endometrial carcinoma for this tumor in hormonesensitive tissue seemed to offer a special situation wherein an apparent relationship between the dysfunctional and the neoplastic might be found. As in the case of other disease, especially tumors, we have been given the possibility of curing many patients so afflicted, and even witnessed in our professional lifetime the definition and wide acceptance of an endometrial cancer precursor, without understanding the mechanism of the disease.
Epidemiology
While the studies of Christopherson et al. (1971) , the age-specific Birmingham data of Taylor (1969) and those of the State of Connecticut (Wynder et al. 1966 ) indicate a significant rise in the incidence of endometrial carcinoma, others deny this rise. It is alleged by Cramer et al. (1974) that the increasing life expectancy of women and the control of cervix cancer have emphasized endometrial cancer. In fact it is gradually becoming the predominant uterine cancer problem in industrialized countries.
The disparity between its incidence in rich and poor in industrialized countries has its geographic counterpart in developing countries, for the incidence in Asia, Africa and South America is very low compared to that in North America and Europe (Doll et al. 1970 ). In the USA the ageadjusted rate in whites is 20.1 (per 100 000) compared to that for blacks which is 9.3 -more than twice as high in the generally more affluent group (Cramer et al. 1974) .
While Asian women generally have a low incidence of endometrial and breast cancer, one must be wary of characterizing distant populations as homogeneous. For example, the very high rate of stomach cancer in-Japan seems to be reduced as one moves southward in the Japanese Islands (T Hirayama, personal communication) while the prevalence rate of nasopharyngeal cancer in Chinese increases as one moves from North to South (Ho 1967 , Shanmugaratnam 1973 Furthermnore, migrant studies of Japanese moving to Hawaii and California are especially intriguing for there is a distinct change in tumor incidence, especially noted in the Nisei and Sansei (first and second American born generations). Their rate of stomach cancer goes down, colon cancer goes up, as does the rate of endometrial and breast disease more modestly (Haenszel & Kurihara 1968 ) -the latter especially during the childbearing period (Stemmerman & Lipkovic 1969) . It is interesting and perhaps appropriate to the endometrial problem that the rate of latent prostate cancer in Japanese in Japan and those in Hawaii is similar while the rate of invasive prostate cancer, very low in Japan, rises in Hawaiian Japanese toward Caucasian high levels. This suggests a growth promoting factor in the Western environment for this tumor (Akazaki & Stemmerman 1973) .
Hawaii is a most appropriate focus for cancer epidemiologists. They are probably attracted not only by the equable climate, splendid beaches and general tropical ambiance, but by the ethnicity; for the population is composed of approximately one-third Caucasian, one-third Japanese and one-third Chinese, Hawaiian and Filipinos. An excellent tumor registry helps iecord keeping in this sequestered island population, especially One gains the impression of an internal migrant phenomenon in an analysis of the mortality rate for endometrial cancer in the white and black populations of the United States; while that for whites has remained steady since 1950, the rate for blacks appears to have risen significantly (National Cancer Institute 1971) . This time period coincides with a steady migration of the southern rural negro to improved economic circumstances in the industrialized cities of the North. Similarly, K Masubuchi (personal communication) reports an increase in endometrial carcinoma and diabetes in Tokyo as the Japanese have adopted a Westerntype high protein, high animal fat diet.
Two areas of special epidemiologic interest are Manila in the Philippines, a very 'Westernized' oriental city where the risk for breast and endometrial cancer appears notably higher than that in other Asian cities (T Hirayama, personal communication); and the prevalence of cervix and endometrial cancer in Israel (Steinitz & Costin 1971) where Israelis of European origin have a Western pattern with a high corpus incidence and very low cervix incidence, while those of Afiican origin have an 'oriental' mode.
If I may speculate about these geographic differences in tumor incidence, I must conclude that it is probable that environmental influences are dominant over genetic ones. Further consideration leads one to the speculation that dietary influence may play a role, especially in endometrial carcinoma, for here nutritional status is significant and it impinges upon the endocrine system. Fig 1 illustrates such a possible mechanism. We have all seen amenorrhea and failure of ovulation occur with striking weight gain or loss.
The Hormonal Milieu I am sure I need not review the constellation of endocrine stigmata in the prototype patient with endometrial cancer. Suffice it to say that the circumstantial evidence for hormone sensitivity provided by these clinical observations is strong but inevitably incomplete: obesity, infertility, coincidence of functioning, ovarian tumors, coincidence of the cystic ovarian syndrome and failure of ovulation, dysfunctional bleeding, diabetic diathesis, effect of progesterone on metastatic endometrial cancer, adenocarcinoma of cervix and vagina in adolescent offspring of diethylstilbestrol treated mothers, development of endometrial carcinoma in young women treated with estrogen for ovarian agenesis and induction of precursor with exogenous estrogens. The high risk for endometrial carcinoma in large, obese women has been known for many years (Corscaden & Gusberg 1947) and studied with more precise epidemiologic methods recently to reveal (Wynder et al. 1966 ) that women 21-50 lb (9.5-23 kg) over average weight have a three times greater risk while those 51 lb (23 kg) or more overweight have a ninefold greater risk; those with increased height also were at greater risk, even independent of obesity. A recent Boston study presented by MacMahon (1974) states that the upper third of weight distribution subjects suffer a 1.8 times greater risk while the upper 15% of their group showed a 2.4 times greater risk, both compared to the lower twothirds of the weight distribution subjects. This study found nulliparity to produce a twofold risk over those with one child and a threefold risk over those with five children; in addition, diabetics incurred a 2.8 times risk; and those with menopause beyond age 52 a 2.4 fold risk which held even for those whose cancer occurred in the 60-69 or over-70 age groups.
These indices, together with the knowledge of the powerful proliferative effect of estrogen upon its target tissues, reinforced by more precise knowledge of the estrogen effect upon RNA synthesis surely must provoke rethinking of the problems of hormone sensitivity for endometrial carcinoma. Indeed the newer steroid metabolic technology has offered a firm basis for such studies for the first time. Prior to this era all evidence was derived as suggested above from observations of clinical failure of hormonal homeostasis or hormonal iatrogenic chance. It has been suggested that these are numerators in search of denominators.
Since breast and endometrial cancers tend to correlate in the same kinds of populations (Dunn 1974) it may be of interest to take note of some steroid excretion studies reported by Brown in 1958 wherein administered estradiol was excreted as estriol in greater ratio by those with breast cancer than in controls. Partition excretion studies in breast cancer have been the subject of much interest (Lennon et al. 1966 , Bulbrook et al. 1971 since that time, and recently MacMahon et al. (1971) have suggested a screening mechanism by their demonstration that in a group of young Asian women (15-19 years of age) destined to have a low rate of breast and endometrial cancer compared to Caucasians, there is a higher ratio of estriol over estrone and estradiol in the urine. Studies by our group (Hausknecht & Gusberg 1969) did show that postmenopausal women with endometrial carcinoma tend to excrete less total estriol as compared to estrone than do normal women in the same age group. This interests us for studies in our laboratories (Tseng & Gurpide 1974) have demonstrated that estriol competes tor the estradiol binding site. It would appear that double isotope dilution techniques (Gurpide et al. 1964) , steroid receptor site technology and radioimmunoassay will permit fresh insights into the pathophysiology of this disease. Surely steroid studies at the blood and at the tissue level will be more meaningful than urinary studies alone.
MacDonald et al. (1969) bave demonstrated that the adrenal precursor A 4-androstenedione is undoubtedly the estrogen prehormone in postmenopausal women and their group and Longcope (1971) reported twice the conversion rate of androstenedione to estrone in this age group as compared to cycling women. MacDonald et al. also noted that postmenopausal bleeders had a higher conversion rate than controls and since that time our group (Hausknecht & Gusberg 1973 ) and theirs (MacDonald & Siiteri 1974) have demonstrated that postmenopausal women with endometrial cancer have a significantly higher conversion rate to estrone than controls. Rubin et al. (1972) in our laboratory have also shown the ratio of estrone to estradiol in plasma to be higher in those women with endometrial cancer.
With androstenedione as the prehormone and estrone the postmenopausal estrogen, it would appear that aging, obese women with endometrial cancer have a significant production rate of estrone. In fact, MacDonald & Siiteri (1974) have suggested that the conditions that put women at high risk for endometrial carcinoma either have a high plasma androstenedione (cystic ovarian syndrome with infertility, ovarian stromal hyperplasia), or have an increased conversion rate to estrone (aging and obesity). In fact their studies show a 15-20-fold increase in conversion in markedly obese older women compared to a young slender counterpart. Schindler et al. (1972) have reported a three-fold increased conversion rate in fat in vitro from patients with endometrial cancer over those with benign disease though they do not give the weight or age of their patients. Twombley et al. (1961) in a study after injection of 14C-labelled estradiol, showed less excretion in obese than lean subjects and speculated that estrogen could be stored in fat and gradually escape giving chronic stimulation. Double isotope dilution studies stimulated by the technique of Gurpide in our group give promise of further elucidation of these problems, though metabolic tissue studies may be still more significant (Gurpide & Welch 1969) .
The early work of Jensen (1960) on selective binding of estradiol by the rat uterus opened this field of research and inevitably led to the analysis of target tissues and tumors in hormone-sensitive sites for estradiol receptor sites. Brush et al. (1968) reported that several endometrial cancers showed estradiol uptake and since that time their group ) and ours have shown estradiol receptors in significant numbers of aging patients with endometrial cancer. Rubin in our laboratory (Rubin et al. 1972 ) studied these tumors systematically and we have demonstrated specific estradiol receptors in 32 % of the tumors without age correlation or relation to differentiation. Terenius et al. (1971) have also shown estradiol binding and they claim a relationship to the differentiation of the tumor. McGuire & Julian (1971) working with animal mammary tumors and Jensen et al. (1971) claimed specific binding that was hormone dependent. Indeed, Jensen et al. in a study of human breast cancer reported that only one of 29 with negative estradiol receptors responded to adrenalectomy whereas 10 of 13 responded who had demonstrable receptors.
At this time before progesterone receptor site studies (Edwards 1973 , Rao & Weist 1974 ) are further developed, or adrenalectomy performed for advanced endometrial carcinoma, one can only suggest that those endometrial tumors with estradiol receptors may or may not respond, but that those lacking demonstrable binding will not respond to hormonal manipulation.
As yet the hypophyseal hormones are incompletely studied in this disease, but LH and FSH radioimmunoassay by our group has failed to show a difference between those with endometrial carcinoma and postmenopausal controls (C J Cohen, M Fogel, R Ossowski & S Y Chen, unpublished data).
It has been noted that tumors in hormonesensitive tissuesbreast, endometrium and prostatepeak at a time of life when these organs are involuting or atrophic. It would appear from the above studies of alternative sites of secretion of prehormone, the receptivity of aging tissues, and the extra-glandular capacity for aromatization, that one cannot discount steroid stimulation of these otherwise involuting organs. That pre-conditioning may exist genetically or otherwise determined would suit both laboratory animal and human evidence.
As a clinician, I am somewhat timid about presenting epidemiologic or hormonal data but I have been emboldened by personal travel to some of the geographic areas described and of course by the generosity of my talented steroid colleagues in collaborating in my whimsical projects. Before I mire myself in any further steroid difficulties before this distinguished group I would like to consider several clinical problems.
Control By Screening
It seems logical that control of this disease should require knowledge of high risk factors, the definition of precursors and construction of a protocol of treatment that includes an account of virulence parameters. It has become commonplace to consider those women with obesity, infertility, failure of ovulation and dysfunctional bleeding of the menopause as subjects at high risk for adenomatous hyperplasia and endometrial carcinoma.
The history of this precursor concept may be abstracted as follows in a North American view: Of course, many others have made contributions to this knowledge since that time and our recent survey of prospective studies with relatively short follow up (Gusberg 1974) showed an 18.5 % progression from adenomatous hyperplasia to carcinoma in a combined series of 562 patients excluding those lost to follow up or treated immediately by hysterectomy. In our own series a cumulative risk of 30 % at ten years was demonstrated over controls (Gusberg & Kaplan 1963) .
At the risk of being repetitive, I shall be precise about our definitions of these precursors for semantic variations have been counterproductive. Adenomatous hyperplasia is characterized by intense proliferation of the glandular epithelium with proliferating glands frequently showing pseudostratification in a back-to-back pattern. There is an increasing order of severity (Gusberg & Kardon 1971) :
Type I: The mild form with areas of an intense microcystic pattern as the glands proliferate actively. Type II: The moderate form with epithelial infolding and protrusion into the gland lumen and occasional budding indicating a more intense metaplastic change. Type III: The severe form is characterized by the full-blown picture of epithelial protrusion and budding, glands back-to-back and a pallor of the glandular epithelium or eosinophilic staining indicating its dysplastic quality. The use of the term Dysplasia by Magnus Haines (Haines & Taylor 1962) and Claud Taylor (1969) seems appropriate in this stage.
Though biologically a cancer precursor, we have refrained from calling Type III adenomatous hyperplasia cancer-in-situ because of the impure criteria for invasion in the endometrium and because it is frequently reversible, especially in young women by the exhibition of progestin or the induction of ovulation. It lies on the borderline between the dysfunctional and the neoplastic.
Raven & Roe (1967) have referred to the difficulty in separating the stages in the development of cancer in hormone-target tissues and this is surely in accord with our experience in the case of endometrial carcinoma. We have diagnosed carcinoma-in-situ in our laboratory on infrequent occasions when a cluster ofendometrial glands exhibits anaplasia and free replication without apparent local restraint, yet apparently confined to a focus of well-differentiated malignant change, described in the past as adenoma malignum. This lesion is not reversible though it may be removed at times by local excision, i.e. curettage. This therapeutic observation should be considered in evaluating the result of treatment of these lesions by hormonal manipulation.
Premenopausal adenomatous hyperplasia, occasionally discovered in young women with cystic ovarian syndrome and failure of ovulation, may be treated by induction of ovulation if infertility is a problem; in others, cycling with progestin will effect reversion to normal except for an occasional refractory endometrium.
Perimenopausal adenomatous hyperplasia is diagnosed by tissue sampling. While cytologic screening has a low rate of efficiency for endometrial carcinoma if the sample is taken in a conventional manner, it can diagnose endometrial cancer efficiently if the cytologic sample is taken directly from the endometrial cavity. However, to this date very few cytologists claim accuracy in the diagnosis of endometrial cancer precursors.
Our group has reported the accuracy of aspiration curettage (Cohen et al. 1974 ) and we believe that, since it does not require anesthesia, it should be used as a histologic screening measure for all high-risk women at the menopause, and perhaps when we gain more experience we shall apply it to all menopausal women.
If Type I or Type II adenomatous hyperplasia is found, one may choose to observe only with repeat tissue sampling at six-month intervals or treat with progestin then rebiopsy. Since we are dealing with a spectrum of disease, there will be some patients with Type II disease for whom hysterectomy will be preferred by patient and therapist.
With Type III adenomatous hyperplasia (dysplasia) and cancer-in-situ (adenoma malignum) a formal diagnostic curettage should follow aspiration curettage to rule out contiguous adenocarcinoma. For these lesions, cancer prophylaxis and definitive treatment of the accompanying uterine bleeding has been accomplished best by hysterectomy in our hands.
Postmenopausal adenomatous hyperplasia: With the current fashion for prophylactic estrogens for postmenopausal women in our country, uterine bleeding frequently ensues. Aspiration curettage will reveal adenomatous hyperplasia in some; since this lesion will have been iatrogenically induced, it will suffice to observe only, without hormonal medication, and repeat the biopsy sample in four months unless bleeding continues. If, however, bleeding occurs spontaneously, without medication, a formal diagnostic curettage is indicated for a significant percentage will harbor true cancer. In those subjects in whom adenomatous hyperplasia is found, if they are generally fit, hysterectomy is indicated.
Control By Treatment It has always appealed to us that cancer treatment should be individualized so that each patient may be treated optimally, receiving adequate treatment for cure but avoiding therapeutic penalties when unnecessary. This requires the identification of virulence factors for endometrial carcinoma. The indices that are clinically applicable at present are: (1) Depth of uterine cavity (size of tumor). (2) Histologic differentiation of tumor (capacity for penetration).
(3) Involvement of the isthmus and cervix (drainage to pelvic lymphatic channels and nodes). In addition, deep myometrial involvement is significant; its presence may be suspected with undifferentiated tumors or established by examination of the specimen postoperatively.
These discriminants have helped us devise a clinical staging that conforms to the aggression of the tumor. It has helped to relieve us of the misapprehension that all endometrial carcinomas are of low grade and easily cured for this impression has been based frequently in the past upon reports of selected series with appropriately favorable results.
Our clinical classification coordinates that correlate with virulence factors are based upon a construction that describes a Stage I tumor as a local 'dependent' one; Stage II as one with 'geographic' or direct local spread; Stage III with lymphatic involvement and the capacity to move to other sites as 'biologic' spread; and Stage IV as a widespread 'autonomous' tumor (Gusberg 1966) . We have utilized, then, a preoperative clinical classification based on the above described virulence factors for in each case an increase in these factors resulted in a decrement in cure rate in our studies (Gusberg & Yannopoulos 1S64) . Thus upon a skeleton of uterine cavity size, we have increased the stage by one order for lack of differentiation of the tumor and/or cervix involvement (Gusberg 1966) . The international classification has now been revised to include these factors and it is now possible by this classification strategy to assess reported cure rates for selection and resolve the surgical versus combined treatment debate of long standing and permit a sliding scale of magnitude of treatment in the hands of gynecologic oncologists.
We have devised our general treatment protocol based upon our classification with simple hysterectomy and bilateral salpingo-oophorectomy for Stage I, combined treatment with preoperative radium packing for Stage II, combined treatment with radical hysterectomy and pelvic lymphadenectomy for Stage Ill and of course individual treatment for Stage IV patients (Gusberg & Yannopoulos 1964) . This general outline permits variations that will suit subgroups:
Stage I tumors of small size and good differentiation may occasionally harbor deep myometrial penetration in the operative specimen; such a subject might receive postoperative vault and parametrial irradiation. Stage III tumors in subjects unsuitable for radical surgery may be treated by radium applied by a cervix plan followed by simple hysterectomy, followed by parametrial irradiation to cover the three primary therapeutic zones. Stage III tumors with greatly enlarged cavities will be more suitable for preoperative external irradiation rather than radium packing. Stage IV tumors will require consideration of combinations of surgery, irradiation, hormonal or chemotherapeutic modalities. It would seem logical to offer para-aortic fields in addition to pelvic irradiation for those patients with ovarian involvement.
Summary
Epidemiologic studies can provide us with etiological clues and help us recognize high risk factors.
The definition of high risk factors, especially in the perimenopausal years can lead to prophylactic measures that may aid in the control of endometrial cancer.
Recognition of the high risk patient in the perimenopausal years by aspiration curettage of ambulatory women may offer a significant strategy of surveillance.
The advent of modem steroid metabolic technology promises to help us clarify the problems of hormone sensitivity of this tumor so that we may properly translate these data into therapeutic action.
Virulence scales can help the choice of treatment for invasive carcinoma so that patients with tumors of low virulence do not suffer from an excess of complications nor those with tumors of high virulence an excess of failure to control. In this manner we can define the role of radiotherapy and surgery, elect combined treatment when indicated and select radical surgery as indicated.
There is evidence to suggest that the developmental concept of this tumor may lead to its control in a manner similar to that occurring with cervix cancer.
